# Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

> **NCT03364608** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 86 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** AS MDI 90 μg
- **DRUG:** AS MDI 180 µg
- **OTHER:** Placebo MDI
- **DRUG:** Proventil 90 μg
- **DRUG:** Proventil 180 μg

## Key facts

- **NCT ID:** NCT03364608
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-03-30
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364608, "Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03364608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*